SecBot SecBot
8-K ·Filed Feb 25, 2026

XNCR

Xencor Inc
BULLISH
Impact 7/10
Horizonmonths Processed8mo ago SEC0001326732-26-000014
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

Traders should monitor upcoming clinical data readouts in 2H26 for XmAb819 and XmAb541, which could serve as significant value inflection points. The strong cash position and extended runway reduce near-term dilution risk.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.55
T+0 close · Feb 25, 2026 · via day close
Latest settled
−16.53%
T+60 · $11.31
Vs SPY
−24.70%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $13.55entry
  2. T+1 · 9mo ago −5.76%α −5.28% · $12.77
  3. T+5 · 9mo ago −17.64%α −16.48% · $11.16
  4. T+20 · 8mo ago −9.15%α −2.74% · $12.31
  5. T+60 · 6mo ago −16.53%α −24.70% · $11.31
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xencor reported financial results for Q4 and full year 2025, showing increased revenue and improved net loss compared to 2024, driven by collaboration and royalty income. The company highlighted clinical progress across its pipeline, including XmAb819 and XmAb541 in oncology and XmAb942 in inflammatory bowel disease, with key data expected in 2026. Xencor maintains a strong cash position and expects to end 2026 with $400–430 million in cash, sufficient to fund operations through 2028.

Key Financial Metrics

Revenue
$125.6M
+13.7% YoY
EPS
$-1.24

Key Facts

  • Revenue increased 13.7% YoY to $125.6 million in 2025, driven by Alexion and Incyte license agreements.
  • Net loss narrowed significantly to $91.9 million ($1.24 EPS) in 2025 vs. $232.6 million ($3.58 EPS) in 2024.
  • Cash, cash equivalents, and marketable securities totaled $610.8 million as of December 31, 2025.
  • Xencor expects to end 2026 with $400–430 million in cash and sufficient runway through 2028.
  • Key clinical catalysts expected in 2H26, including dose-expansion data for XmAb819 and XmAb541, and initiation of a first-in-human study for XmAb412.

Financial Impact

Revenue increased by $15.1 million YoY to $125.6 million; net loss decreased by $140.7 million YoY to $91.9 million.

revenuenet lossepscash

Risk Factors

  • Clinical trial setbacks could delay or derail development timelines.
  • Reliance on partnership revenue from Alexion and Incyte creates execution and dependency risk.
  • Market volatility in biotech sector may impact stock performance despite strong fundamentals.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001326732-26-000014
Document: xncr-20260225.htm0001326732-26-000014
Document: 0001326732-26-000014-index-headers.html0001326732-26-000014
Document: 0001326732-26-000014-index.html0001326732-26-000014
Document: 0001326732-26-000014.txt0001326732-26-000014

Track record

20 reports on XNCR

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +67.24% at T+60 after the May 5, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $35.40 Now $35.40 +0.00% settles Nov 18
  2. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $39.23 Now $35.40 −9.77% settles Nov 17
  3. Nov 12, 20264d ago Insider Cluster Neutral 4/10 Entry $37.09 to $35.40 Now $35.40 −4.56% ▼ −4.56% −2.65% vs SPY
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $38.13 to $37.09 Now $35.40 −7.16% ▼ −2.73% −2.36% vs SPY
  5. Nov 10, 20266d ago 144 Neutral 3/10 Entry $39.97 to $38.13 Now $35.40 −11.43% ▼ −4.60% −4.25% vs SPY
  6. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $35.75 to $38.59 Now $35.40 −0.98% ▲ +7.94% +5.58% vs SPY
  7. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $34.05 to $35.75 Now $35.40 +3.96% ▲ +4.99% +4.68% vs SPY
  8. Oct 30, 202617d ago SC 13G/A Bearish 4/10 Entry $29.82 to $29.66 Now $35.40 −18.71% ▲ +0.54% +0.06% vs SPY
  9. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $29.99 to $29.21 Now $35.40 +18.04% ▼ −2.60% −2.22% vs SPY
  10. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $29.18 to $29.99 Now $35.40 +21.32% ▲ +2.78% +2.22% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 25, 2026